Miktan (Tamsulosin Hydrochloride)

Tamsulosin Hydrochloride, the active ingredient in Miktan, is a Alpha-1 adrenergic antagonist presented as an oral tablet for oral use. It is indicated for the treatment of benign prostatic hyperplasia in adult men, helping to improve urinary flow and reduce associated symptoms such as urgency, frequency, and nocturia.

GNH USA supplies Miktan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks across Europe, Asia, Africa and the Americas, and adhering to stringent quality standards.

Miktan (tamsulosin hydrochloride) acts on the alpha-1 adrenergic pathway to relieve urinary obstruction caused by prostate enlargement.

- Benign prostatic hyperplasia (BPH): Improves urinary flow and reduces symptoms such as hesitancy, weak stream, and nocturia. - Lower urinary tract symptoms (LUTS) associated with BPH: Alleviates frequency, urgency, and incomplete bladder emptying. - Acute urinary retention secondary to BPH: Facilitates bladder emptying and reduces the need for catheterisation.

Tamsulosin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Nasal congestion - Abnormal ejaculation - Orthostatic hypotension - Dry mouth

Serious or Rare Side Effects: - Severe hypotension or syncope - Priapism - Allergic reactions such as rash or urticaria - Angioedema - Liver enzyme elevations - Persistent erectile dysfunction

Before initiating therapy with Miktan, several safety considerations should be reviewed.

- Cardiovascular assessment: Evaluate blood pressure and risk of orthostatic hypotension. - Prostate evaluation: Exclude prostate cancer before starting treatment. - Hepatic function: Use caution in patients with moderate to severe liver impairment. - Concomitant alpha‑blockers: Avoid simultaneous use with other α‑blockers to prevent additive hypotension. - CYP3A4 inhibitors: Monitor when co‑administered with strong CYP3A4 inhibitors such as ketoconazole. - Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Tamsulosin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase tamsulosin plasma levels and risk of hypotension. - Other α‑adrenergic antagonists (e.g., prazosin, doxazosin): Can cause additive blood pressure lowering.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): May modestly raise tamsulosin concentrations. - Antihypertensive agents (e.g., ACE inhibitors, diuretics): May enhance hypotensive effect. - NSAIDs: May increase risk of renal impairment when combined with tamsulosin. - Digoxin: Monitor for potential changes in serum levels.